function getval(val){
 var a1=val.replace(/<\/?.+?>/g,"");
 var a2=a1.replace(/ /g,"");
 return a2;
}
//document.write('http://wxzl.cogonline.com/html/CeShiZhuanLanYi/ShiBin/ZhiNaWenXian/702.html');
wx.config({
debug:  false, 
appId: 'wx85d01b1d7184c45d',
timestamp: 1714671030,
nonceStr: 'VkTWGyJBh8pJ26lD',
signature: '248a84923dee8672cec90ff84cf9840d4dd45af7',
jsApiList: [ 
   'checkJsApi', 
   'onMenuShareTimeline', 
   'onMenuShareAppMessage', 
   'onMenuShareQQ', 
   'onMenuShareWeibo'
]
});
wx.ready(function () { 
	wx.onMenuShareTimeline({  
	title: '周建维教授：卵巢癌中的免疫检查点抑制剂：何去何从?', 
	link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/ShiBin/ZhiNaWenXian/702.html',
	imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
	success: function () {
		//alert('fx-ok');
	},
	cancel: function () {
		//alert('fx-no');
	}
	});
	wx.onMenuShareAppMessage({  
		title: '周建维教授：卵巢癌中的免疫检查点抑制剂：何去何从?', 
		link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/ShiBin/ZhiNaWenXian/702.html',
		imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
		desc: getval('大量回顾性研究表明，在上皮性卵巢癌(OC)中，瘤内免疫细胞浸润密度与预后有关，为在卵巢癌中探索PD-1和PD-L1抑制剂的疗效提供了理论依据。而迄今为止评估复发卵巢癌患者PD1/PD-L1抑制剂的临床试验多令人失望。今天邀请到浙江大学医学院附属第二医院妇科周建维教授，为大家分享一篇发表在《医学肿瘤学治疗进展》的综述，《Immune checkpoint inhibitors in ovarian cancer: where do we stand?》。在这篇综述中，作者讨论了单药PD1/PD-L'),
		success: function () {
			//alert('fx-ok');
		},
		cancel: function () {
			//alert('fx-no');
		}
	});
});	
wx.error(function (res) {
	//alert(location.href.split('#')[0]);
	//alert('err:'+res.errMsg);  
});
if(location.href.indexOf("?") >= 1 ){
	location.href=location.href.substring(0,location.href.indexOf("?"));
}